Table 1.
Subject characteristics
| Received LUM/IVA | Not received LUM/IVA | ||
|---|---|---|---|
| Number | 10 | 10 | |
| Age (range) years | 26.5 (19–56) | 30.6 (24–47) | P = 0.9 |
| Sex M:F | 6:4 | 5:5 | |
| BMI | 21.5 (3.3) | 21.8 (3.0) | P = 0.8 |
| FEV1% predicted | 36.3 (2.8) | 40.1 (6.6) | P = 0.1 |
| Range | (32.4–40.1) | (32.1–44.3) | |
| FVC% predicted | 66.4 (12.2) | 66.5 (12.2) | P = 0.8 |
| Range | (51.4–77.2) | (50.8–76.5) | |
| TLC (% predicted) | 98.11 (16) | 95.7 (1.4) | P = 0.8 |
| FRC (% predicted) | 122 (36.3) | 124 (15.1) | P = 0.8 |
| RV (% predicted) | 200.4 (69.6) | 198 (53) | P = 0.7 |
| DLCO (% predicted) | 58 (14.6) | 63 (18.2) | P = 0.6 |
| 6 MWT m | 532.4 (90.1) | 546 (81.3) | P = 0.8 |
| CF related diabetes | 5 | 5 | |
| Pseudomonas | 9 | 9 | |
| Burkholderia Cenocepacia | 1 | 1 | |
| Number of exacerbations in the previous 12 months requiring IV antibiotics | 3 (4.6) | 2.8 (5.6) | P = 0.8 |
| Using regular nebulised DNase | 10 | 10 | NA |
| Using regular Azithromycin | 8 | 9 | P = 0.9 |
| Using regular nebulised antibiotics | 9 | 9 | P = 0.8 |